Analyses of tumor evolution in DIPG patients have indicated that H3F3A, HIST1H3B, and ACVR1 mutations occur very early during tumorigenesis, and are positively selected during tumor progression (Hoffman et al., 2016, Nikbakht et al., 2016, Vinci et al., 2018). This evidence concerns the gene ACVR1 and neoplasm.